Zacks Research Has Negative Outlook of PRE FY2027 Earnings

Prenetics Global Limited (NASDAQ:PRE) – Zacks Research lowered their FY2027 EPS estimates for shares of Prenetics Global in a research note issued on Tuesday, August 18th. Zacks Research analyst B. Sorensen now forecasts that the company will post earnings of $1.49 per share for the year, down from their prior estimate of $1.56. The consensus estimate for Prenetics Global’s current full-year earnings is ($1.28) per share.

Other research analysts also recently issued research reports about the company. Benchmark increased their target price on Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Wall Street Zen downgraded Prenetics Global from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a research report on Friday, July 17th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $34.25.

Prenetics Global Price Performance

Shares of PRE opened at $18.76 on Thursday. Prenetics Global has a one year low of $7.18 and a one year high of $23.63. The firm has a market capitalization of $316.48 million, a P/E ratio of -4.51 and a beta of 0.26. The business has a fifty day moving average of $19.13 and a 200 day moving average of $18.88.

Prenetics Global (NASDAQ:PRE) last released its quarterly earnings results on Tuesday, August 18th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.11. The firm had revenue of $46.49 million for the quarter, compared to analysts’ expectations of $49.02 million. Prenetics Global had a negative return on equity of 19.46% and a negative net margin of 47.43%.

Hedge Funds Weigh In On Prenetics Global

Several large investors have recently added to or reduced their stakes in PRE. 683 Capital Management LLC bought a new position in shares of Prenetics Global in the fourth quarter worth approximately $1,181,000. Manatuck Hill Partners LLC bought a new stake in shares of Prenetics Global during the 4th quarter valued at $170,000. T3 Companies LLC bought a new stake in shares of Prenetics Global during the 4th quarter valued at $170,000. Kingsview Wealth Management LLC purchased a new position in shares of Prenetics Global during the 4th quarter valued at $172,000. Finally, OMERS ADMINISTRATION Corp purchased a new position in shares of Prenetics Global during the 4th quarter valued at $307,000. Hedge funds and other institutional investors own 25.01% of the company’s stock.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.